- Home
- UHT vs CTNM Comparison
UHT vs CTNM Comparison
Compare UHT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UHT | CTNM |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.5M | 550.7M |
| IPO Year | 1995 | 2024 |
Fundamental Metrics
Financial Performance| Metric | UHT | CTNM |
|---|---|---|
| Price | $41.84 | $16.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $43.00 | $19.00 |
| AVG Volume (30 Days) | 88.8K | ★ 504.6K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $99,190,000.00 | N/A |
| Revenue This Year | $2.12 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $52.20 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $35.26 | $8.60 |
| 52 Week High | $46.30 | $17.35 |
Technical Indicators
Market Signals| Indicator | UHT | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 60.93 |
| Support Level | $39.72 | $13.65 |
| Resistance Level | $43.06 | $16.81 |
| Average True Range (ATR) | 1.04 | 1.06 |
| MACD | -0.03 | 0.17 |
| Stochastic Oscillator | 52.12 | 76.92 |
Price Performance
Historical ComparisonAbout UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.